Cancer bronchique à petites cellules : traitements de première ligne et maintenance

Finally, this article describes new perspectives: clinicians expect a lot from the analysis of genotypic alterations in SCLC. A few steps have been made and a new target is already known: DLL3 (Delta Like Protein 3), which is NOTCH ligand. If anti-angiogenic therapies' influence is too weak to go on trying in this direction, immunotherapies, using modern immuno-oncologic treatment, are still giving some hope. But let's remain careful because these therapies are still on development and studies are going on.